Broad nucleoside reverse-transcriptase inhibitor cross-resistance in human immunodeficiency virus type 1 clinical isolates.
about
Current Scenario of HIV/AIDS, Treatment Options, and Major Challenges with Compliance to Antiretroviral TherapyStructural Basis for the Role of the K65R Mutation in HIV-1 Reverse Transcriptase Polymerization, Excision Antagonism, and Tenofovir ResistanceHIV-1 Reverse Transcriptase (RT) Polymorphism 172K Suppresses the Effect of Clinically Relevant Drug Resistance Mutations to Both Nucleoside and Non-nucleoside RT InhibitorsApricitabine does not select additional drug resistance mutations in tissue culture in human immunodeficiency virus type 1 variants containing K65R, M184V, or M184V plus thymidine analogue mutationsCriteria for drugs used in pre-exposure prophylaxis trials against HIV infectionHIV-1 drug-resistance surveillance among treatment-experienced and -naïve patients after the implementation of antiretroviral therapy in GhanaNovel high-throughput screen identifies an HIV-1 reverse transcriptase inhibitor with a unique mechanism of actionHIV-1 drug resistance and resistance testing.Abacavir-lamivudine versus tenofovir-emtricitabine for initial HIV-1 therapyClinically relevant genotype interpretation of resistance to didanosineThe Role of Nucleotide Excision by Reverse Transcriptase in HIV Drug Resistance.HIV-1 drug resistance in the iPrEx preexposure prophylaxis trial.Drug resistance in non-B subtype HIV-1: impact of HIV-1 reverse transcriptase inhibitors.In vitro antiretroviral activity and in vitro toxicity profile of SPD754, a new deoxycytidine nucleoside reverse transcriptase inhibitor for treatment of human immunodeficiency virus infection.Efficacy and safety of a dual boosted protease inhibitor-based regimen, atazanavir and fosamprenavir/ritonavir, against HIV: experience in a pediatric populationChanging patterns in the selection of viral mutations among patients receiving nucleoside and nucleotide drug combinations directed against human immunodeficiency virus type 1 reverse transcriptase.Comparison of the Mechanisms of Drug Resistance among HIV, Hepatitis B, and Hepatitis C.Fitness comparison of thymidine analog resistance pathways in human immunodeficiency virus type 1.Dose-response curve slope is a missing dimension in the analysis of HIV-1 drug resistance.Major HIV resistance mutations in untreated Romanian patients.Rapid development of antiretroviral drug resistance mutations in HIV-infected children less than two years of age initiating protease inhibitor-based therapy in South Africa.Consensus drug resistance mutations for epidemiological surveillance: basic principles and potential controversies.Drug resistance and viral tropism in HIV-1 subtype C-infected patients in KwaZulu-Natal, South Africa: implications for future treatment optionsPre-exposure prophylaxis and antiretroviral resistance: HIV prevention at a cost?The use of preexposure treatments for HIV prophylaxisRecent advances in the treatment of HIV/AIDS.Modifying Antiretroviral Therapy in Virologically Suppressed HIV-1-Infected Patients.HIV-1 genetic diversity and drug resistance among Senegalese patients in the public health system.Resistance to reverse transcriptase inhibitors used in the treatment and prevention of HIV-1 infection.Apricitabine: a novel deoxycytidine analogue nucleoside reverse transcriptase inhibitor for the treatment of nucleoside-resistant HIV infection.Nucleoside reverse transcriptase inhibitor resistance mutations associated with first-line stavudine-containing antiretroviral therapy: programmatic implications for countries phasing out stavudineGenetic Diversity and Drug Resistance Mutations in HIV-1 from Untreated Patients in Niamey, NigerHIV-1 drug resistance mutations: an updated framework for the second decade of HAARTPanel of prototypical infectious molecular HIV-1 clones containing multiple nucleoside reverse transcriptase inhibitor resistance mutations.Evolving uses of oral reverse transcriptase inhibitors in the HIV-1 epidemic: from treatment to preventionReverse transcriptase inhibitors as potential colorectal microbicides.The nucleoside analogue D-carba T blocks HIV-1 reverse transcription.Transmitted HIV drug resistance in treatment-naive Romanian patientsLow-abundance resistant mutations in HIV-1 subtype C antiretroviral therapy-naive individuals as revealed by pyrosequencing.Clinical significance of HIV reverse-transcriptase inhibitor-resistance mutations.
P2860
Q26750980-285592AF-B635-46EE-B273-DDD58A4B09B8Q27657718-A4C37B39-D0AE-49C6-A9AA-678376C18CF3Q27670634-8F5C9750-C70E-4FEA-998A-8F862E6F4B7AQ28235418-F4B237FF-4A36-4C7B-B9AB-B3584AF8405FQ28469067-98F183D2-5E85-4C00-BC02-D1CFDFBB8FEDQ28535421-7F30EED6-A20F-4245-8006-339A755E102FQ28829256-2B60D861-C7BE-456F-8906-0764CCEB8F3BQ30245693-F03B0E56-DBD6-495A-8C1D-C49863CA1CCAQ33565604-1108E4C9-FBE3-43AC-A9E8-F51C8AE6F6B3Q33770146-12F6F4CE-0E1F-4E0C-9A6B-FDC19A3CAE44Q33889635-FDD2794F-6714-4B72-9A7D-E76B9ECE25C8Q34249966-3AE90704-AA7B-4DDD-BC32-2BE8B1C8407CQ34303603-273CCC27-117C-4751-BC42-D6D0D325658FQ34352006-31096F66-42AB-4B1F-905D-FEC5881B4A54Q34367468-584444CC-A603-4604-BBCC-00EA6109A106Q34414078-9F805825-1A5A-4EA8-9715-42375F171909Q34489239-02D4F4BB-8F00-4355-ACCA-4B3D1F164570Q34717892-2ADDC7DB-80D8-422A-B719-B5539DE49BE0Q34937254-6897227D-0069-429F-BBFC-42F4C2234123Q35071197-800AD2C7-B28C-4AEE-85BA-FB8F351A63ABQ35179391-872805D3-53C3-4AC3-AF1F-C0371C17B9D8Q35300021-25BA33A8-3671-423B-99B9-A4BE5C3C0E07Q35386184-E9E311B9-122D-43C2-A98C-1F6F6E70E0CFQ35636514-3071FA57-E25A-40BD-80E9-CD52A29F8444Q35760180-30425139-EAE1-4510-947B-046F415AAEF4Q35917365-2C5AF48E-464A-4A10-A660-605AD9909EB0Q36426953-3FAD52E9-8BE2-4A71-B8DB-684C686ED6EEQ36558909-C039222D-45D1-44B3-8D33-1B18DE059C89Q36744634-306DC109-CD0F-4F4D-83D6-4047CDA498FAQ36836868-139925E8-2EEA-4A78-BDBF-6609A58A18A3Q36852626-7AF442A9-9D15-4205-82F4-BF038AD5C2BBQ36858549-FCFC49EE-A699-4D1F-A9A4-30F079FD2401Q36900010-04861626-426A-4F64-9123-5031C489663EQ36950131-5140210A-43FA-4115-B58B-D65D0D4E1FBEQ37071435-81946E58-8812-40A8-BBF9-02CB1B6AD8DAQ37190754-CF625DEB-CBDD-41A7-A627-7CEE2E976E08Q37374652-8B0D5F3B-15EC-404B-93BF-178D78093D3DQ37495405-460D74A2-7AFF-44D9-8BE8-5C883329EAF4Q37734688-9230363C-315C-4BB7-9250-74754DE860BEQ37859395-858FED30-CDF7-4F07-B5B7-18F68BBB9FAB
P2860
Broad nucleoside reverse-transcriptase inhibitor cross-resistance in human immunodeficiency virus type 1 clinical isolates.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh-hant
name
Broad nucleoside reverse-trans ...... irus type 1 clinical isolates.
@en
Broad nucleoside reverse-trans ...... irus type 1 clinical isolates.
@nl
type
label
Broad nucleoside reverse-trans ...... irus type 1 clinical isolates.
@en
Broad nucleoside reverse-trans ...... irus type 1 clinical isolates.
@nl
prefLabel
Broad nucleoside reverse-trans ...... irus type 1 clinical isolates.
@en
Broad nucleoside reverse-trans ...... irus type 1 clinical isolates.
@nl
P2093
P356
P1476
Broad nucleoside reverse-trans ...... irus type 1 clinical isolates.
@en
P2093
Colombe Chappey
Jeannette M Whitcomb
Neil T Parkin
Nicholas S Hellmann
P304
P356
10.1086/378281
P407
P577
2003-09-16T00:00:00Z